drugset
drugset / Trial / NCT02334982

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants

NCT02334982 ↗

Phase 1 Completed 47 enrolled Takeda
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to characterize the safety and tolerability profile of TAK-137 when administered as a single dose of tablets at escalating dose levels in healthy participants.

Timeline

Start
2013-06
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-137 Unknown 0.5 mg Oral
Subject TAK-137 Unknown 2 mg Oral
Subject TAK-137 Unknown 5 mg Oral
Subject TAK-137 Unknown 10 mg Oral
Subject TAK-137 Unknown 20 mg Oral

Indications

No indication recorded.